These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 18937622)

  • 21. A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin.
    Yiu KH; Cheung BM; Tse HF
    Expert Opin Investig Drugs; 2010 Mar; 19(3):437-49. PubMed ID: 20141348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels.
    Capuzzi DM; Morgan JM; Weiss RJ; Chitra RR; Hutchinson HG; Cressman MD
    Am J Cardiol; 2003 Jun; 91(11):1304-10. PubMed ID: 12767421
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance.
    Linke A; Sonnabend M; Fasshauer M; Höllriegel R; Schuler G; Niebauer J; Stumvoll M; Blüher M
    Atherosclerosis; 2009 Jul; 205(1):207-13. PubMed ID: 19131065
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in the understanding and management of dyslipidemia: using niacin-based therapies.
    Ito MK
    Am J Health Syst Pharm; 2003 Jul; 60(13 Suppl 2):S15-21; quiz S25. PubMed ID: 12901026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Important considerations for treatment with dietary supplement versus prescription niacin products.
    Backes JM; Padley RJ; Moriarty PM
    Postgrad Med; 2011 Mar; 123(2):70-83. PubMed ID: 21474895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Niacin's role in the statin era.
    Brooks EL; Kuvin JT; Karas RH
    Expert Opin Pharmacother; 2010 Oct; 11(14):2291-300. PubMed ID: 20569085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia.
    Viljoen A; Wierzbicki AS
    Drug Healthc Patient Saf; 2010; 2():61-71. PubMed ID: 21701618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Practical management of dyslipidemia with elevated lipoprotein(a).
    Riche DM; East HE; Priest HM
    J Am Pharm Assoc (2003); 2008; 48(6):803-7. PubMed ID: 19019811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients.
    Morgan JM; Capuzzi DM; Guyton JR
    Am J Cardiol; 1998 Dec; 82(12A):29U-34U; discussion 39U-41U. PubMed ID: 9915660
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Niacin-based therapy for dyslipidemia: past evidence and future advances.
    Ito MK
    Am J Manag Care; 2002 Sep; 8(12 Suppl):S315-22. PubMed ID: 12240703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients.
    McKenney JM; Proctor JD; Harris S; Chinchili VM
    JAMA; 1994 Mar; 271(9):672-7. PubMed ID: 8309029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overview of niacin formulations: differences in pharmacokinetics, efficacy, and safety.
    Pieper JA
    Am J Health Syst Pharm; 2003 Jul; 60(13 Suppl 2):S9-14; quiz S25. PubMed ID: 12901025
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Niacin extended-release/lovastatin: combination therapy for lipid disorders.
    Moon YS; Kashyap ML
    Expert Opin Pharmacother; 2002 Dec; 3(12):1763-71. PubMed ID: 12472373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nicotinic acid: recent developments.
    Kamanna VS; Vo A; Kashyap ML
    Curr Opin Cardiol; 2008 Jul; 23(4):393-8. PubMed ID: 18520725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study.
    Goldberg AC
    Am J Cardiol; 1998 Dec; 82(12A):35U-38U; discussion 39U-41U. PubMed ID: 9915661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
    J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol.
    Sakai T; Kamanna VS; Kashyap ML
    Arterioscler Thromb Vasc Biol; 2001 Nov; 21(11):1783-9. PubMed ID: 11701466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.
    Fazio S; Guyton JR; Polis AB; Adewale AJ; Tomassini JE; Ryan NW; Tershakovec AM
    Am J Cardiol; 2010 Feb; 105(4):487-94. PubMed ID: 20152243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
    Ahmed MH
    J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.